Ali J. Satvat's most recent trade in BridgeBio Pharma Inc was a trade of 8,425 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on June 20, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| BridgeBio Pharma Inc | Ali J. Satvat | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2025 | 8,425 | 8,425 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Pharma Inc | Ali J. Satvat | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jun 2025 | 6,589 | 165,993 (0%) | 0% | 0 | Common Stock | |
| Coherus Biosciences Inc | Ali J. Satvat | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2025 | 112,000 | 112,000 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Pharma Inc | Ali J. Satvat | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.99 per share. | 30 Dec 2024 | 79,702 | 79,702 (0%) | 0% | 11.0 | 875,925 | Common Stock |
| BridgeBio Pharma Inc | Ali J. Satvat | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2024 | 79,702 | 0 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Pharma Inc | Ali J. Satvat | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2024 | 39,851 | 0 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Pharma Inc | Ali J. Satvat | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Dec 2024 | 39,851 | 0 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Pharma Inc | Ali J. Satvat | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 26.21 per share. | 30 Dec 2024 | 39,851 | 159,404 (0%) | 0% | 26.2 | 1,044,495 | Common Stock |
| BridgeBio Pharma Inc | Ali J. Satvat | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 16.68 per share. | 30 Dec 2024 | 39,851 | 119,553 (0%) | 0% | 16.7 | 664,715 | Common Stock |
| BridgeBio Pharma Inc | Ali J. Satvat | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2024 | 26,014 | 26,014 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Pharma Inc | Ali J. Satvat | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2023 | 51,501 | 51,501 | - | - | Stock Option (right to buy) | |
| BridgeBio Pharma Inc | Ali J. Satvat | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Jun 2022 | 104,921 | 104,921 | - | - | Stock Option (right to buy) | |
| BridgeBio Pharma Inc | Ali J. Satvat | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 38,895 | 38,895 | - | - | Stock Option (right to buy) | |
| BridgeBio Pharma Inc | Ali J. Satvat | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2021 | 79,702 | 79,702 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Pharma Inc | Ali J. Satvat | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2021 | 39,851 | 39,851 | - | - | Stock Option (Right to Buy) | |
| BridgeBio Pharma Inc | Ali J. Satvat | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2021 | 39,851 | 39,851 | - | - | Stock Option (Right to Buy) |